Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TVB-2640 |
Synonyms | |
Therapy Description |
TVB-2640 is a fatty acid synthase (FASN) inhibitor that inhibits lipid metabolism in tumor cells (PMID: 26519059, PMID: 31630414). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TVB-2640 | TVB2640|TVB 2640 | FASN Inhibitor 5 | TVB-2640 is a fatty acid synthase (FASN) inhibitor that inhibits lipid metabolism in tumor cells (PMID: 26519059, PMID: 31630414). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03808558 | Phase II | TVB-2640 | Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas | Recruiting | USA | 0 |
NCT02980029 | Phase I | TVB-2640 | Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer | Recruiting | USA | 0 |
NCT02223247 | Phase I | TVB-2640 | A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors | Completed | USA | GBR | 0 |